Syndax Announces Participation in September Investor Conferences

Syndax Pharmaceuticals (Nasdaq:SNDX) will participate in two September 2026 investor conferences in New York.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq:SNDX) will participate in two September 2026 investor conferences in New York. CEO Michael A. Metzger and the management team are scheduled for fireside chats at the Citi 2026 Biopharma Back to School Conference on September 10 at 8:40 a.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15 at 10:00 a.m. ET. Live webcasts and limited-time replays will be accessible via the Investor section of Syndax’s website.

Argus Sep 1 session 11 alerts

+4.20% close to close 1.5x rel. volume Open Argus

Details

News Market Reaction – SNDX

$1.80B Mkt Cap at Peak Alert

On Sep 1, the day this news came out, SNDX closed 4.20% above the previous close. Our momentum scanner recorded 11 alerts for this stock that day. Relative volume reached 1.5x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 1 session.

Key Figures

Citi conference date: September 10, 2026 Citi fireside chat time: 8:40 a.m. ET H.C. Wainwright conference date: September 15, 2026 +1 more

Citi conference date

September 10, 2026

Fireside chat

Citi fireside chat time

8:40 a.m. ET

September 10, 2026

H.C. Wainwright conference date

September 15, 2026

Fireside chat

H.C. Wainwright fireside chat time

10:00 a.m. ET

September 15, 2026

Historical Context

5 past events · Latest: Aug 05

5 events

1. Aug 05

   Inducement grant notice

   24h Move

   -0.8%

   Granted inducement options covering 59,250 shares to five new employees.

2. Aug 04

   2Q26 earnings report

   24h Move

   +4.4%

   Quarterly revenue growth and narrowed loss supported a positive earnings reaction.

3. Jul 28

   Earnings scheduling notice

   24h Move

   -4.3%

   Announced the August 4 results date and conference call logistics.

4. Jul 14

   Pipeline event

   24h Move

   +5.4%

   Presented late-stage programs and introduced SNDX-4321 and SNDX-62122.

5. Jul 01

   Inducement grant notice

   24h Move

   +4.5%

   Granted inducement stock options covering 250,700 common shares to eight employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fda-approved, menin inhibitor, monoclonal antibody, csf-1 receptor

4 terms

fda-approved regulatory

"Revuforj® (revumenib), an FDA-approved menin inhibitor"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

menin inhibitor medical

"Revuforj® (revumenib), an FDA-approved menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

monoclonal antibody medical

"Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

csf-1 receptor medical

"antibody that blocks the colony stimulating factor 1 (CSF-1) receptor"

A cell-surface protein found mainly on certain immune cells that acts like a lock for signaling molecules such as colony-stimulating factor 1; when those molecules bind, the receptor tells the cell to grow, move or change behavior. As a biological control point in inflammation, tissue repair and some cancers, it is a common drug target; investors watch drug candidates and clinical results involving the receptor because they can affect the commercial and regulatory prospects of biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

• Citi 2026 Biopharma Back to School Conference in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
• H.C. Wainwright 28th Annual Global Investment Conference in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
  
  

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Syndax (SNDX) present at the Citi 2026 Biopharma Back to School Conference?

Syndax is scheduled for a fireside chat at the Citi 2026 Biopharma Back to School Conference on September 10, 2026, at 8:40 a.m. ET. According to Syndax, the session will feature CEO Michael A. Metzger and will be webcast live on the company’s investor webpage.

What is the date and time of Syndax (SNDX) presentation at the H.C. Wainwright 28th Annual Global Investment Conference?

Syndax plans a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 10:00 a.m. ET. According to Syndax, the event will be held in New York and streamed via a live webcast on its investor site.

How can investors access the Syndax (SNDX) webcasts for the September 2026 investor conferences?

Investors can access live webcasts of Syndax’s September 2026 fireside chats through the Investor section of www.syndax.com. According to Syndax, replays will be available for a limited time, allowing shareholders and analysts to review the discussions afterward.

Who will represent Syndax (SNDX) at the September 2026 investor conferences?

Syndax will be represented by Chief Executive Officer Michael A. Metzger and members of its management team. According to Syndax, they will participate in fireside chats at both the Citi 2026 Biopharma Back to School Conference and the H.C. Wainwright 28th Annual Global Investment Conference.

What therapies are in Syndax (SNDX) pipeline mentioned alongside its September 2026 conference participation?

Syndax highlights Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved CSF-1 receptor–blocking antibody. According to Syndax, the company is conducting several clinical trials to further develop its oncology pipeline across the treatment continuum.